Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibr...
March 25 2020 - 9:00AM
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel therapeutics to treat cystic fibrosis and
other diseases caused by nonsense mutations limiting production of
functional proteins, today announced that enrollment in our Phase 2
clinical trials for ELX-02 in cystic fibrosis have been temporarily
paused in response to the COVID-19 pandemic. Our goals are to avoid
unnecessary exposure in at-risk populations, to maintain the
integrity of our study data and to support global healthcare
providers in their commitment to ensure patient safety.
Public health authorities worldwide have recommended that people
at high risk stay at home as much as possible, cancel non-essential
doctor’s visits and avoid unnecessary exposure to people and public
spaces. Cystic Fibrosis patients, especially those with nonsense
mutations, have compromised lung function and may be at increased
risk of severe illness in the event of a COVID-19 infection.
“Enrollment in our Phase 2 clinical trials in cystic fibrosis
has been temporarily paused as the health
and safety of our employees, healthcare workers, and patients must
be our highest priority during this crisis. In accordance with the
guidance provided by the U.S. Centers for Disease Control, World
Health Organization and national, state and local governments in
the United States and abroad, we are taking appropriate steps to
help flatten the COVID-19 infection curve and reduce the risk in
the most vulnerable patients,” said Dr. Gregory Williams, Chief
Executive Officer of Eloxx. “COVID-19 is rapidly evolving and we
continue to work closely with our clinical sites and investigators.
We remain committed to completing enrollment in this Phase 2 proof
of concept clinical trial program and reporting top line data as
soon as feasible. We will provide further updates when
appropriate.”
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing novel RNA-modulating drug
candidates (designed to be eukaryotic ribosomal selective
glycosides) that are formulated to treat rare and ultra-rare
premature stop codon diseases. Premature stop codons are point
mutations that disrupt protein synthesis from messenger RNA. As a
consequence, patients with premature stop codon diseases have
reduced or eliminated protein production from the mutation bearing
allele accounting for some of the most severe phenotypes in these
genetic diseases. These premature stop codons have been identified
in over 1,800 rare and ultra-rare diseases.
Read-through therapeutic development is focused on extending
mRNA half-life and increasing protein synthesis by enabling the
cytoplasmic ribosome to read through premature stop codons to
produce full-length proteins. Eloxx’s lead investigational product
candidate, ELX-02, is a small molecule drug candidate designed to
restore production of full-length functional proteins. ELX-02 is in
the early stages of clinical development focusing on cystic
fibrosis and cystinosis. ELX-02 is an investigational drug that has
not been approved by any global regulatory body. Eloxx’s
preclinical candidate pool consists of a library of novel drug
candidates designed to be eukaryotic ribosomal selective glycosides
identified based on read-through potential. Eloxx recently
announced a new program focused on rare ocular genetic disorders.
Eloxx is headquartered in Waltham, MA, with operations in Rehovot,
Israel. For more information, please visit www.eloxxpharma.com.
Forward-Looking Statements This press
release contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections,
and speak only as of the date they are made. We undertake no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and
uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, including: the
development of the Company’s read-through technology; the approval
of the Company’s patent applications; the Company’s ability to
successfully defend its intellectual property or obtain necessary
licenses at a cost acceptable to the Company, if at all; the
successful implementation of the Company’s research and development
programs and collaborations; the Company’s ability to obtain
applicable regulatory approvals for its current and future product
candidates; the acceptance by the market of the Company’s products
should they receive regulatory approval; the timing and success of
the Company’s preliminary studies, preclinical research, clinical
trials, and related regulatory filings; the ability of the Company
to consummate additional financings as needed; as well as those
discussed in more detail in our Annual Report on Form 10-K and our
other reports filed with the Securities and Exchange
Commission.
Contact:
Barbara Ryan 203-274-2825barbarar@eloxxpharma.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2023 to Apr 2024